Roflumilast (ALTANA Pharma AG), a phosphodiesterase-4 (PDE4) inhibitor, is being developed for the management of chronic obstructive pulmonary disease (COPD) and asthma. Its once-daily oral ...
However, none of the PDE4 inhibitors tested so far has reached the market, mainly owing to tolerability issues such as emesis. A study in Nature Biotechnology that sheds light on the structural ...
In a new study, researchers found that a PDE4 inhibitor increased salivation because of PDE4 inhibition in the salivary glands and in the autonomic nervous system, which regulates involuntary body ...
Hosted on MSN7mon
FDA Approves Novel Nebulized Therapy for COPDThe FDA approved inhaled ensifentrine (Ohtuvayre) as maintenance treatment for chronic obstructive pulmonary disease (COPD) in adults, drugmaker Verona Pharma announced on Wednesday. A first-in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback